<p>Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women</p>

• DOI: 10.2147/clep.s194056
• Publication Date: 2019-07-17T21:33:23Z
• Authors: Yupeng Liu; Xiaosan Zhang; Hongru Sun; Shu Zhao; Yuxue Zhang; Dapeng Li; Qingyuan Zhang; Yashuang Zhao
• Keywords: meta-analysis; 03 medical and health sciences; 0302 clinical medicine; Clinical Epidemiology; Infectious and parasitic diseases; RC109-216; primary breast cancer risk; bisphosphonates; Original Research; 3. Good health

Prevention of primary breast cancer (BCa) in women is great public health importance. The existing results from observational epidemiologic studies focused on the association between bisphosphonates and BCa risk have been inconsistent.To update this systematic review meta-analysis to assess effect risk.We comprehensively searched MEDLINE, EMBASE, Cochrane libraries, ProQuest, Web Science through June 25, 2018 for relevant studies.Epidemiological that assessed women.We reported according PRISMA guidelines. Available multivariable-adjusted estimates corresponding 95% CIs were pooled with a random-effects model.The prespecified main outcome was BCa.In total, five cohort involving 657,558 12,991 patients, three population-based case-control 54,701 cases 237,962 healthy controls two randomized controlled trials (RCTs) 13,774 165 patients included meta-analysis. Bisphosphonates associated 12% decreased (RR, 0.88; CI, 0.83-0.94). However, when we analyzed study designs separately, inconsistent RCTs. observed long-term use (≥1 year) seemed be more robust stronger than short-term (<1 0.75; 0.66-0.84; 0.90; 0.84-0.97; respectively).This adds body evidence an significantly BCa. future large-scale RCTs are required validate concern.